Quality Breakdown,A potent glucose-dependent insulinotropic peptide

Glucagon-like peptide 1 (7-36) amide, often abbreviated as GLP-1 (7-36) amide, is a fascinating and critically important peptide hormone with significant implications for glucose metabolism and potential therapeutic applications. This molecule, a truncated form of GLP-1, is primarily produced by the L-cells in the intestinal lining and plays a pivotal role as an incretin. Understanding its function, production, and characteristics is essential for comprehending its physiological significance, particularly in the context of diabetes and metabolic disorders.

The Genesis and Nature of GLP-1 (7-36) Amide

Glucagon-like peptide 1 (7-36) amide is derived from the post-translational processing of proglucagon. This precursor protein, found in the mucosal endocrine cells of the intestine, undergoes enzymatic cleavage to yield several peptides, including the biologically active GLP-1 (7-36) amide. This specific form is characterized by an amide group at its C-terminus, distinguishing it from other GLP-1 variants. The sequence of GLP-1 (7-36) amide is identical in various species, including human, rat, mouse, and porcine, highlighting its conserved biological importance. The peptide's molecular weight is approximately 3297.67 Daltons, with the molecular formula C149 H226 N40 O45.

Physiological Roles and Actions

As a potent glucose-dependent insulinotropic peptide, GLP-1 (7-36) amide exerts its primary effect by stimulating insulin secretion from pancreatic beta cells in a manner that is dependent on blood glucose levels. This means it enhances insulin release when glucose is high, but does not significantly impact it when glucose is normal or low, thus minimizing the risk of hypoglycemia. This crucial characteristic makes it a highly attractive target for therapeutic interventions.

Beyond its role in insulin secretion, GLP-1 (7-36) amide is involved in several other physiological processes:

* Suppression of Glucagon Secretion: It effectively reduces the secretion of glucagon, a hormone that raises blood glucose levels, further contributing to glucose homeostasis.

* Gastric Emptying and Motility: GLP-1 (7-36) amide slows down gastric emptying, which helps to regulate the absorption of nutrients and prevent post-meal glucose spikes. It also influences gastric motility.

* Appetite Regulation: Emerging research suggests that GLP-1 (7-36) amide may play a role in reducing appetite and promoting satiety, contributing to weight management.

* Cardiovascular Effects: Studies have indicated potential beneficial effects of GLP-1 on the cardiovascular system, although more research is ongoing in this area.

* Hepatic Glucose Uptake: In vitro studies suggest that GLP-1 (7-36) amide can enhance hepatic glucose uptake, meaning the liver takes up more glucose from the bloodstream.

The physiological role of glucagon-like peptide-1 7-36 amide in humans was investigated as early as 1987, with studies confirming its potent insulin secretagogue properties. Research has shown that intravenous administration of GLP-1 (7-36) amide can normalize plasma glucose in non-insulin-dependent diabetic (NIDDM) patients, demonstrating its therapeutic potential.

Research and Therapeutic Applications

The potent insulinotropic and glucose-lowering effects of GLP-1 (7-36) amide have made it a significant focus of pharmaceutical research. While the native peptide has a short half-life due to rapid degradation by the enzyme dipeptidyl peptidase-4 (DPP-4), significant efforts have been dedicated to developing stable analogs and therapeutic strategies that leverage its mechanisms.

These efforts have led to the development of GLP-1 receptor agonists, a class of drugs that mimic the action of GLP-1 (7-36) amide and are widely used in the management of type 2 diabetes. These medications have demonstrated efficacy in improving glycemic control, promoting weight loss, and reducing the risk of cardiovascular events in patients with type 2 diabetes.

Researchers utilize high-quality amino acids, resins, and reagents to synthesize and study GLP-1 (7-36) amide and its analogs for various cellular and molecular biology applications. The peptide is available in different forms, such as amide acetate, for research purposes. GLP-1 (7-36) acid is another related form that has also been studied for its effects on metabolic parameters.

Key Entities and LSI Keywords

* Entity: Glucagon-like peptide 1 (7-36) amide, GLP-1 (7-36) amide, GLP-1, Proglucagon, L-cells, Pancreatic beta cells, Incretin, DPP-4 enzyme.

* **